In vitro antifungal susceptibility of filamentous fungi causing rare infections: Synergy testing of amphotericin B, posaconazole and anidulafungin in pairs

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 8, 2012, Pages 1937-1940

  Drogari Apiranthitou, Maria ^a,b   Mantopoulou, Foteini Despina ^a   Skiada, Anna ^a   Kanioura, Lambrini ^b   Grammatikou, Maria ^a   Vrioni, Georgia ^b   Mitroussia Ziouva, Aggeliki ^a,b   Tsakris, Athanassios ^b   Petrikkos, George ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chequerboard; Fusarium; Hyaline moulds; Mucorales; Mucormycetes; Zygomycetes

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; FUNGUS; FUNGUS ISOLATION; FUSARIUM MONILIFORME; FUSARIUM OXYSPORUM; FUSARIUM PROLIFERATUM; FUSARIUM SOLANI; HYALOHYPHOMYCETE; IN VITRO STUDY; LICHTHEIMIA RAMOSA; MINIMUM INHIBITORY CONCENTRATION; MOULD; MUCOR; MUCOR CIRCINELLOIDES; MUCORMYCETE; NONHUMAN; PAECILOMYCES; PAECILOMYCES LILACINUS; PAECILOMYCES VARIOTII; RHIZOPUS; RHIZOPUS ARRHIZUS; RHIZOPUS MICROSPORUS; RHIZOPUS STOLONIFER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG SYNERGISM; ECHINOCANDINS; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; TRIAZOLES;

EID: 84864523178     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks137     Document Type: Article

References (12)

1. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-71.
2. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
3. EUCAST. EUCAST DEFINITIVE DOCUMENT E.DEF 9.1: Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds. 2008. http://www.escmid.org/fileadmin/src/media/PDFs/4ESCMID_Library/3Publications/EUCAST_Documents/Other_Documents/EUCAST_moulds_DEFINITIVE_document_V_ISO_April_08%20final.pdf (7 March 2012, date last accessed).
4. Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715.
5. Pfaller MA, Messer SA, Boyken L et al. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis 2003; 45: 241-4.
6. Almyroudis NG, Sutton DA, Fothergill AWet al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51: 2587-90.
7. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol 2007; 20: 695-704.
8. Arikan S, Sancak B, Alp S et al. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008; 46: 567-73.
9. Philip A, Odabasi Z, Rodriguez J et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49: 3572-4.
10. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-7.
11. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1,3-b-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721-7.
12. Guembe M, Guinea J, Peláez T et al. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother 2007; 51: 3457-8.